Marlena S Fejzo

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
    Marlena S Fejzo
    Division of Hematology Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Int J Mol Sci 14:3094-109. 2013
  2. ncbi Change in paternity and recurrence of hyperemesis gravidarum
    Marlena S Fejzo
    Department of Maternal Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Matern Fetal Neonatal Med 25:1241-5. 2012
  3. ncbi Tissue microarrays from frozen tissues-OCT technique
    Marlena Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Methods Mol Biol 664:73-80. 2010
  4. ncbi Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK
    Marlena S Fejzo
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 50:434-41. 2011
  5. ncbi Patients with a history of hyperemesis gravidarum have similar symptoms during egg stimulation and develop ovarian hyperstimulation syndrome: case series
    Marlena S Fejzo
    Department of Maternal Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Fertil Steril 93:267.e9-11. 2010
  6. ncbi High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals
    Marlena S Fejzo
    Keck School of Medicine, University of Southern California, Department of Obstetrics and Gynecology, Los Angeles, USA
    Eur J Obstet Gynecol Reprod Biol 141:13-7. 2008
  7. ncbi Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target
    Marlena S Fejzo
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 47:873-83. 2008
  8. ncbi Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins
    M Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
    Am J Pathol 159:1645-50. 2001
  9. ncbi Recurrence risk of hyperemesis gravidarum
    Marlena S Fejzo
    University of California at Los Angeles, Los Angeles, CA, USA
    J Midwifery Womens Health 56:132-6. 2011
  10. ncbi Familial aggregation of hyperemesis gravidarum
    Yafeng Zhang
    Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    Am J Obstet Gynecol 204:230.e1-7. 2011

Collaborators

Detail Information

Publications19

  1. ncbi Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
    Marlena S Fejzo
    Division of Hematology Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Int J Mol Sci 14:3094-109. 2013
    ..Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer...
  2. ncbi Change in paternity and recurrence of hyperemesis gravidarum
    Marlena S Fejzo
    Department of Maternal Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Matern Fetal Neonatal Med 25:1241-5. 2012
    ..To determine whether change in paternity changes recurrence risk of hyperemesis gravidarum (HG)...
  3. ncbi Tissue microarrays from frozen tissues-OCT technique
    Marlena Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Methods Mol Biol 664:73-80. 2010
    ....
  4. ncbi Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK
    Marlena S Fejzo
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 50:434-41. 2011
    ..Further research is necessary to determine whether targeting knockdown of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK...
  5. ncbi Patients with a history of hyperemesis gravidarum have similar symptoms during egg stimulation and develop ovarian hyperstimulation syndrome: case series
    Marlena S Fejzo
    Department of Maternal Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Fertil Steril 93:267.e9-11. 2010
    ..To investigate the symptoms and outcomes of ovarian stimulation in patients with a history of hyperemesis gravidarum...
  6. ncbi High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals
    Marlena S Fejzo
    Keck School of Medicine, University of Southern California, Department of Obstetrics and Gynecology, Los Angeles, USA
    Eur J Obstet Gynecol Reprod Biol 141:13-7. 2008
    ..The goal of this study was to determine the prevalence of severe nausea and vomiting of pregnancy/hyperemesis gravidarum among relatives of affected individuals...
  7. ncbi Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target
    Marlena S Fejzo
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 47:873-83. 2008
    ..Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer...
  8. ncbi Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins
    M Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
    Am J Pathol 159:1645-50. 2001
    ..We show OCT arrays work well for DNA, RNA, and protein analyses, and may have significant advantages over the original technology for the assessment of some genes and proteins by improving both qualitative and quantitative results...
  9. ncbi Recurrence risk of hyperemesis gravidarum
    Marlena S Fejzo
    University of California at Los Angeles, Los Angeles, CA, USA
    J Midwifery Womens Health 56:132-6. 2011
    ..The purpose of this study is to describe the recurrence risk for hyperemesis gravidarum (HG)...
  10. ncbi Familial aggregation of hyperemesis gravidarum
    Yafeng Zhang
    Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    Am J Obstet Gynecol 204:230.e1-7. 2011
    ..This study was undertaken to determine whether there is familial aggregation of hyperemesis gravidarum (HG), making it a disease amenable to genetic study...
  11. ncbi Symptoms and pregnancy outcomes associated with extreme weight loss among women with hyperemesis gravidarum
    Marlena S Fejzo
    University of Southern California, Department of Obstetrics and Gynecology, Los Angeles, California 90033, USA
    J Womens Health (Larchmt) 18:1981-7. 2009
    ..To report the weight loss and associated symptoms experienced by a large cohort of women with hyperemesis gravidarum (HG)...
  12. ncbi Risk factors, treatments, and outcomes associated with prolonged hyperemesis gravidarum
    Patrick M Mullin
    Keck School of Medicine, University of Southern California, Department of Maternal Fetal Medicine, Los Angeles, CA 90095, USA
    J Matern Fetal Neonatal Med 25:632-6. 2012
    ..To identify factors associated with prolonged Hyperemesis Gravidarum (HG)...
  13. ncbi Secular trends in the treatment of hyperemesis gravidarum
    T Murphy Goodwin
    University of Southern California, Keck School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, California, USA
    Am J Perinatol 25:141-7. 2008
    ..Over the past 20 years, multiple treatments have been used for women with HG, with a trend toward treatment with reportedly more effective modalities, such as IV hydration and serotonin inhibitors...
  14. ncbi Periostin promotes ovarian cancer angiogenesis and metastasis
    Min Zhu
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Gynecol Oncol 119:337-44. 2010
    ..In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis...
  15. ncbi Posttraumatic stress symptoms following pregnancy complicated by hyperemesis gravidarum
    Joan Christodoulou-Smith
    Department of Anesthesiology, Children s Hospital Los Angeles, Critical Care Medicine, Los Angeles, CA, USA
    J Matern Fetal Neonatal Med 24:1307-11. 2011
    ..This study explores posttraumatic stress symptoms (PTSS) and negative life outcomes following HG pregnancies...
  16. ncbi Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo
    Zev A Wainberg
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA
    Clin Cancer Res 16:1509-19. 2010
    ....
  17. ncbi Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum
    Borzouyeh Poursharif
    Department of Obstetrics and Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Contraception 76:451-5. 2007
    ..This study was conducted to describe characteristics of women who terminated their pregnancies secondary to hyperemesis gravidarum (HG)...
  18. ncbi Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab
    Ferdows Ather
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e56112. 2013
    ..Neither pAKT nor tAKT was associated with sensitivity...
  19. ncbi Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
    H R Ashar
    Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854, USA
    Cell 82:57-65. 1995
    ..These results, identifying a gene rearranged in a benign neoplastic process that does not proceed to a malignancy, suggest a role for HMGI-C in adipogenesis and mesenchyme differentiation...